These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 8646825)

  • 1. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
    Gramatté T; Oertel R; Terhaag B; Kirch W
    Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil.
    Gramatté T; Oertel R
    Clin Pharmacol Ther; 1999 Sep; 66(3):239-45. PubMed ID: 10511059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
    Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
    Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
    Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
    Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
    Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
    Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.
    Wetterich U; Spahn-Langguth H; Mutschler E; Terhaag B; Rösch W; Langguth P
    Pharm Res; 1996 Apr; 13(4):514-22. PubMed ID: 8710739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat.
    Shirasaka Y; Kuraoka E; Spahn-Langguth H; Nakanishi T; Langguth P; Tamai I
    J Pharmacol Exp Ther; 2010 Jan; 332(1):181-9. PubMed ID: 19779132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
    Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
    Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-dependent small intestinal absorption of ranitidine.
    Gramatté T; el Desoky E; Klotz U
    Eur J Clin Pharmacol; 1994; 46(3):253-9. PubMed ID: 8070507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
    Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
    Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of bicarbonate absorption and its relationship to sodium transport in the human jejunum.
    Turnberg LA; Fordtran JS; Carter NW; Rector FC
    J Clin Invest; 1970 Mar; 49(3):548-56. PubMed ID: 5415681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Griseofulvin absorption from different sites in the human small intestine.
    Gramatté T
    Biopharm Drug Dispos; 1994 Dec; 15(9):747-59. PubMed ID: 7888603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
    Weitschies W; Bernsdorf A; Giessmann T; Zschiesche M; Modess C; Hartmann V; Mrazek C; Wegner D; Nagel S; Siegmund W
    Pharm Res; 2005 May; 22(5):728-35. PubMed ID: 15906167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.
    Zeng Y; He FY; He YJ; Dai LL; Fan L; Zhou HH
    Xenobiotica; 2009 Nov; 39(11):844-9. PubMed ID: 19845435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
    Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
    Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.